Objective: To investigate whether drugs targeting peripheral cannabinoid-1 (CB1) receptor ameliorate adiposity comparable to central CB1-receptor antagonist or not. Measurements: Receptor binding assay and functional assay in vitro. Pharmacokinetic parameters in mice, brain uptake clearance of compounds in rats and antagonism on the CB1-agonist-induced hypothermia in mice. Diet consumption, body weight changes, hepatic gene expression of sterol-regulatory element-binding protein-1 (SREBP-1) and plasma/tissue concentrations of compounds in HF diet-induced obese (HF-DIO) mice after acute and chronic treatment. Results: Compound-1, an SR141716A derivative, is a peripheral CB1-receptor-selective antagonist that is 10 times less potent than SR141716A in in vitro evaluations. Although the plasma concentrations of Compound-1 are five times higher than those of SR141716A, its potency is still 10 times lower than that of SR141716A in reducing the consumption of normal or HF diet by mice. Through evaluations of brain uptake and the effect on CB1-agonist-induced hypothermia, it was verified that the bloodbrain barrier (BBB) penetration of Compound-1 is much lower than that of SR141716A. In HF-DIO mice, chronic treatment by Compound-1 showed dose-dependent antiobesity activities, while its brain distribution was very low as compared with that of SR141716A. Compound-1's effective doses for antiobesity activity were just over 30 mg kg À1 . However, Compound-1 completely suppressed the elevated hepatic SREBP-1 expression even at 10 mg kg À1 . Conclusion: These results suggest that (1) central CB1 receptors mediate anorectic response of CB1-receptor antagonists and (2) peripheral modulations, including SREBP-1 expression, are not major mechanisms in the antiobesity effects of CB1-receptor antagonists.
Introduction
It is well established that the endocannabinoid (EC) system is involved in physiological regulation of many functions, including energy homeostasis, through activities in the central and peripheral nervous systems. Central cannabinoid-1 (CB1) receptors are distributed in the hypothalamus where they directly regulate orexigenic or anorexigenic signals. 1 Central activation of CB1 receptors modulates the energy balance and feeding behavior, resulting in stimulation of food intake. 2 However, they are also present in peripheral tissues including the gut, 3 the liver and hepatocytes, 4 and white adipose tissue. 5 There are many reports that peripheral CB1 receptors are also involved in the antiobesity effects of CB1-receptor antagonist. Activation of hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. 4, 6 Furthermore, the EC system contributes to fat accumulation by acting directly on the proliferation 7 and differentiation of adipose tissue. 8 SR141716A (N-(piperidin-1-yl)-5-4-chlorophenyl)-1-2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride) (code name for rimonabant, withdrawn from the markets since October 2008), a CB1-receptor antagonist and also classified as an inverse agonist, modulates food intake by acting on CB1 receptors located on capsaicin-sensitive sensory terminals. 9 Pavon et al. 10, 11 demonstrated that LH-21, a peripherally acting neutral CB-receptor antagonist, has antiobesity effects in vivo. Thereafter, Chen et al. 12 suggested that LH-21 does not act on the CB1 receptor to inhibit food intake in mice. Even though it is a controversial issue, it is suggested that the antiobesity effects of CB1-receptor antagonists may be related to the effects on the peripheral EC system, including the liver and white adipose tissues, as well as the central EC system. 13 Several CB1-receptor antagonists, including SR141716A, have been reported to be effective in obese animal models 14 and in patients. 15 Although SR141716A has been approved in Europe for treatment of obesity, psychiatric side effects such as depression have not been completely resolved yet. 6, 15 Finally, even the European Medicine Agency recommended suspending sales of SR141716A in October 2008. 16 One possible solution to overcome these limitations is to verify the pharmacological characteristics of peripheral CB1-receptor-selective antagonists. According to recent report, the blocker acting on peripheral CB1 receptors is an alternative approach to salvage it from the demise of a drug class that was once anticipated to yield blockbusters. 6 Intriguingly, a therapeutic role for CB1-receptor antagonists in depressive disorders was reported in animals. 17 These contrasting results may imply that it is not easy to eliminate the psychiatric side effects when a CB1 antagonist is acting upon the central CB1 receptor. We have synthesized a series of SR141716A derivatives and examined their pharmacological properties. In this study, we characterized the properties of a peripheral CB1-receptorselective antagonist designated as Compound-1 ((E)-N-(3-chlorobenzyl)-3-(5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)acrylamide). To the best of our knowledge, this is the first report comparing the importance of central and peripheral CB1-receptor blockade using pharmacodynamic and pharmacokinetic tools.
Materials and methods

Materials
SR141716A and Compound-1 were synthesized at Ajou University, Korea. WIN55212-2 and CP55,940 were purchased from Tocris (Ellisville, MO, USA). [ 3 H]CP55,940 was purchased from PerkinElmer Life and Analytical Sciences (Boston, MA, USA). Customized primers used for reverse transcription-polymerase chain reaction (RT-PCR) were synthesized and purchased from Genotech (Daejon, Korea). HF diet (D12492) was purchased from Research Diet (New Brunswick, NJ, USA). Other chemical reagents without special mention were obtained from Sigma-Aldrich (St Louis, MO, USA). Unless otherwise specified, materials and reagents for cell culture were purchased from Invitrogen (Grand Island, NY, USA). Hydroxypropylmethylcellulose (50%) and methylcellulose (0.5%) were used as vehicles for Compound-1 and SR141716A, respectively.
Animals
All experiments were performed in accordance with guidelines from the Institutional Animal Care and Use Committee of Research Center, Dong-A Pharm. Co. Ltd. Sprague-Dawley rats and C57BL/6 mice were obtained from Dae Han Biolink (Eumsung, Korea). The animals were maintained under a controlled environment, with temperature at 23 ± 2 1C, relative humidity at 55±5% and a 12-h/12-h light/dark cycle throughout the experiment. The animals were given food and UV-sterilized tap water ad libitum.
Rat CB1-receptor preparation The methods for membrane preparation from rat cortex have been described elsewhere. 18 Male Sprague-Dawley rats were decapitated and brains excluding the cerebellum were rapidly removed and dissected on ice. Brain cortices from five rats in a homogenize solution (320 mM sucrose, 2 mM EDTA, 5 mM MgCl 2 ) were homogenized with a Diax 900 homogenizer. The homogenate was centrifuged at 1600 g for 10 min and the resulting supernatant was centrifuged at 39 000 g for 15 min. The pellet was resuspended in buffer-A (50 mM Tris/HCl, pH 7.4, 5 mM MgCl 2 , 2mM EDTA), incubated for 10 min at 37 1C and centrifuged at 23 000 g for 10 min. The membrane were resuspended in buffer-A, incubated at 30 1C for 40 min and centrifuged at 11 000 g for 15 min. The final pellet was resuspended in buffer-B (50 mM Tris/HCl, pH 7.4, 3 mM MgCl 2 , 1mM EDTA) to 5B10 mg protein per milliliter and divided into small aliquots for storage at À70 1C.
Rat CB2-receptor preparation Male Sprague-Dawley rats were decapitated and spleens were rapidly removed. The spleens were homogenized in buffer-A with the Diax 900 homogenizer. The homogenate was centrifuged at 1100 g for 10 min and the supernatant was centrifuged for 30 min at 45 000 g. The pellet was resuspended in buffer-B to 10-20 mg protein per milliliter and divided into small aliquots and stored at À70 1C.
CB1/2 receptor binding assay
The receptor binding assays were conducted as described elsewhere. 19 Compounds were dissolved in dimethyl sulf- 
Pharmacokinetics in mice
Male C57BL/6 mice were fasted overnight and were administered a single oral dose of Compound-1 or SR141716A at 10 mg kg À1 . Mice were anaesthetized with diethyl ether and blood samples were collected in heparinized tubes at each time point by retro-orbital sinus bleeding techniques (three heads/each collection time). Blood samples were centrifuged at 9 940 g for 3 min and plasma samples were stored at À20 1C before analysis. Plasma samples were analyzed by LC-MS/MS (API3000; MDS Sciex, Concord, Ontario, Canada). The mobile phase contained 10 mM ammonium acetate (pH 4. Estimation of brain uptake Brain uptake clearance was estimated using a sample pooling method according to the previous study. 20 Male SpragueDawley rats were fasted overnight and the femoral artery and vein were then catheterized using polyethylene tubing under light diethyl ether anesthesia. After recovery from anesthesia, a bolus of cassette-dosing solution (mixture of 1 mg of each compound in 1 ml saline) was administered through the femoral vein. Blood samples were collected five times at intervals of 1 min. The blood samples were centrifuged immediately. For all samples except the first and the last samples, 20 ml aliquots of plasma were collected. For the first and last samples, 10 ml aliquots of plasma were collected and all samples were mixed together. Immediately after obtaining the last blood sample, the rats were killed by decapitation and the whole-brain tissue was collected and weighed. The pooled plasma sample and brain tissue were stored in the freezer at À20 1C. The brain tissue was homogenized with four volumes of tissue using radioimmunoprecipitation assay buffer and a tissue homogenizer. The homogenate was then centrifuged at 13 670 g for 10 min and the supernatant was collected. The collected supernatant of brain samples (100 ml) was extracted by adding 20 ml of internal standard solution (1 ml g À1 ml À1 verapamil) and 800 ml of ethyl acetate. After mixing for 3 min, the samples were centrifuged at 13 670 g for 3 min. A volume of 750 ml of supernatant was evaporated on a centrifugal evaporator (Eyela, Tokyo, Japan). The residue was reconstituted with 150 ml of 50% acetonitrile and 10 ml of each sample was injected directly into the LC-MS/MS system. Analytical methods using LC-MS/MS were identical with those described above.
CB1-agonist-induced hypothermia in mice
Male C57BL/6 mice weighting 18B22 g were housed five heads per cage and allowed at least 7 days for acclimation. Changes in body temperature were monitored by measuring rectal temperature using a rectal probe coupled to a digital thermometer (Natsume, Seisakusyo, Japan). SR141716A (0.3, 1 and 3 mg kg
À1
) or Compound-1 (10, 30 and 100 mg kg À1 ) was orally administrated at 30 min prior to WIN55212-2 application. To characterize the effect of SR141716A or Compound-1 on hypothermia induced by WIN55212-2, body temperature was measured at 10, 30, 60, 120 and 240 min after WIN55212-2 administration (20 mg kg
Food intake in C57BL/6 mice Food intake was measured using slight modifications of previously described methods. 21 Seven to eight-week-old male C57BL/6 mice were fed regular rodent chow (Agribrand Purina 38057). Mice were maintained on a reverse light/dark cycle (light on 2300 to 1100, light off 1100 to 2300) with one animal per cage for a minimum of 7 days before testing. At 18 h before the start of the testing period, all food was removed. The next day mice received either vehicle (0.5% methylcellulose) or test compounds by oral gavage 30 min before the onset of the dark cycle. Subsequently, they were ) or vehicle (0.5% methylcellulose). Compound-1 or SR141716A was administered orally. Twenty-four hours later the amount consumed was calculated.
Chronic effects in HF diet-fed obese mice Male C57BL/6 mice were fed a high-fat (HF) diet. After 23 weeks mice were allocated by body weight to Compound-1 (10, 30 and 100 mg kg ), SR141716A (10 and 30 mg kg À1 ) or vehicle (0.5% methylcellulose). Then they were treated once daily by gavage for 21 days. Body weight and food intake were measured daily. On day 22, non-fasting blood samples were collected and subsequently target tissues (liver, whole brain and adipose tissues) were isolated for use in RT-PCR or for the measurement of tissue distribution. Sample preparation and analytical methods using LC-MS/MS were identical with those described above.
Semi-quantitative RT-PCR analyses
Total RNA was isolated from each liver tissue using TRIzol s reagent (Invitrogen). First-strand cDNA was synthesized from total RNA using oligo(dT) 15 
Statistical analysis
The results are expressed as the mean ± s.e.m. Statistical analysis was performed using SigmaStat 2.0 (SPSS, Chicago, IL, USA). Multi-group comparisons were performed by oneway analysis of variance. When analysis of variance indicated a significant (Po0.05) difference among groups, statistical differences between groups were subsequently evaluated using Student-Newman-Keuls multiple comparison test. A value Po0.05 was considered significant. (Figure 1b) . The affinities for SR141716A and Compound-1 for CB2 receptor were determined using rat spleen membrane fractions and were much higher for CB1 than CB2 (IC 50 2.1 mM and higher than 10 mM, respectively).
Results
Affinity and selectivity for CB receptors
Compound-1 inhibited [ 3 H]CP55,940 binding to rat brain membrane with an IC 50 value of 159.1 nM, whereas SR141716A showed 10-fold higher affinity than Compound-1, with an IC 50 value of 16.0 nM
Antagonistic activity
To investigate the antagonistic activity of Compound-1 on CB1-receptor-mediated response, functional assays were performed. Transient coexpression of CB1 receptors and CRE luciferase in Chinese hamster ovary cells, followed by treatment with CB1-receptor agonist CP55,940, activated luciferase activity in a concentration-dependent manner (data not shown). Treatment with CP55,940 (100 nM) increased basal luciferase activity three-fold. This response was antagonized by Compound-1 or SR-141716A in a concentration-dependent manner with equivalent potencies (IC 50 134 and 155 nM, respectively; Figure 1c ).
Pharmacokinetics in mice
The mean plasma concentration-time profiles and relevant pharmacokinetic parameters of Compound-1 and SR141716A are shown in Figure 2 . The AUC inf and C max of Compound-1 were higher than those of SR141716A (C max 4.8-fold; AUC inf 5.4-fold).
Brain uptake in rats Brain uptake clearance was estimated using a sample pooling method according to a previous study. 20 The concentrations of pooled plasma samples and brain homogenate were measured for determination of the CL app.,uptake (apparent brain uptake clearance). CL app.,uptake was obtained by dividing the amount of drug in brain at 5 min after administration by the area under the plasma concentration-time curve from time zero to 5 min estimated from the pooled sample. CL app.,uptake for Compound-1 and SR14171A were 0.00228 ± 0.000401 and 0.314 ± 0.0807 ml min À1 g brain, respectively (n ¼ 3) (Figure 3 ).
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Effects on CB1-receptor agonist-induced hypothermia Intraperitoneal injection of CB1-receptor agonist, WIN55212-2, evoked a rapid hypothermia response that persisted for several hours. 23 Significant decline in body Central cannabinoid plays a major role in adiposity M-H Son et al temperature began 10 min after the injection. Peak hypothermia was recorded at 30 min after treatment and body temperature gradually recovered toward the baseline (Figure 4 ). SR141716A or Compound-1 was administered at 30 min prior to WIN 55212-2 administration (20 mg kg À1 , intraperitoneal) to determine whether CB1-agonist-induced hypothermia could be recovered. SR141716A dose dependently antagonized the hypothermia produced by WIN55212-2 ( Figure 4a ). However, in the case of Compound-1, hypothermia was significantly antagonized only in the highest dose-treated group (Figure 4b ).
Effects on food intake in C57BL/6 mice
In regular chow-supplied mice, a single oral dose of SR141716A produced a significant and dose-dependent decrease in food intake at doses up to 30 mg kg À1 (Figure 5a ). Percent inhibitions were 19, 52 and 99% for 3, 10 and 30 mg kg À1 of SR141716A, respectively. Administration of Compound-1 also decreased food intake in a doserelated manner, but was not significant at doses of 10 and 30 mg kg À1 . Compound-1 significantly inhibited food intake by 39% at 100 mg kg
À1
. In HF diet-supplied mice, food intakes in SR141716A-treated groups were significantly and dose dependently reduced by 30, 76 and 93%, respectively, whereas those in Compound-1-treated groups were reduced by 20, 62 and 85%, respectively (Figure 5b) . The ED 50 values of Compound-1 and SR141716A were 24.3 and 1.9 mg kg À1 , respectively.
Chronic effects on body weight and food intake Before treatment, mean body weight was 50.2 ± 0.3 g for HF diet-induced obese (HF-DIO) mice and 33.7 ± 0.4 g for lean mice. From day 2, body weight was significantly and dose dependently decreased in Compound-1-(10, 30 and 100 mg kg Central cannabinoid plays a major role in adiposity )-treated groups, food intakes were recovered to the baseline from day 12 and 13 ( Figure 6b ).
Tissue distribution
After the chronic effects for Compound-1 and SR141716A in HF-DIO mice were observed, plasma and tissue distribution were determined. At 10 mg kg À1 dose, the plasma concentration of Compound-1 was higher than that of SR141716A, which is consistent with our results from the pharmacokinetic study of mice (Table 1 ). Mean T/P ratios (tissue concentration divided by plasma concentration) of Compound-1 and SR141716A were 41 and were similar in liver and white adipose tissues. However, the T/P ratio of Compound-1 in brain was much lower than that of SR141716A, suggesting that Compound-1 might be distributed in brain to a lesser extent than SR141716A.
Semi-quantitative RT-PCR analysis of SREBP-1c
Since SREBP-1c has been shown to be a peripheral molecular target of the EC system, 4 we examined whether chronic treatment of HF-fed mice with both CB1 antagonists could decrease the gene expression of SREBP-1c in the liver, using RT-PCR. In HF diet-fed mice, the expression levels of hepatic SREBP-1c were markedly increased as compared with those in the lean control (Po0.05). Treatment of SR141716A (30 mg kg
À1
) resulted in a significant decrease in the hepatic level of SREBP-1c. However, a low dose (10 mg kg
) of Compound-1 that showed no antiobesity effect strongly reduced the gene expression of SREBP-1c to the level seen in the lean control (Po0.05 versus HF-DIO control; Figure 7 ).
Discussion
Numerous studies support the important role of CB1 receptors in orexigenic signaling and put forward the CB1 receptor as a potential therapeutic target for obesity. In this study, Compound-1 was identified as a potent, selective and more peripherally active antagonist of CB1 receptor.
In receptor binding assay, Compound-1 showed a selective and high affinity for rat CB1 receptor. In functional assay, Compound-1 and SR141716A inhibited CB1-receptor agonist-mediated luciferase activities in a concentration-dependent manner. These results demonstrate that Compound-1 is a selective antagonist for CB1 receptor, with a potency 10-fold less than SR141716A. Central cannabinoid plays a major role in adiposity M-H Son et al
In pharmacokinetic studies of mice, T max and elimination half-lives of Compound-1 and SR141716A were very similar except C max . Consequently, Compound-1 unexpectedly showed five times higher exposure than SR141716A. However, preliminary experiments revealed that Compound-1 exhibited weak antiobesity activity in vivo (Figure 5a ). One of possible hypotheses for these differences is that the permeability of Compound-1 across the blood-brain barrier (BBB) is significantly lower than that of SR141716A. These results let us study the rate of uptake for these compounds by the brain in rats.
We adopted the sample pooling method that is reasonably accurate for measurement of brain uptake kinetics and suitable for accelerated assessment in vivo.
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The CL apparent,uptake of reference drugs were coincided with previously reported results. Under these assay conditions, Compound-1 is significantly less permeable into the brain tissue than theophyllin, which is known as a less permeable xanthine analog. 24 On the other hand, SR141716A showed high CL apparent,uptake comparable to metoclopramide or quinine, agents known to be permeable to the BBB. 25 These results mean that Compound-1 cannot reach the brain tissues as efficiently as SR141716A. To verify these characteristics of Compound-1, we further examined its antagonistic effect on CB1-receptor agonist-induced hypothermia. The anterior nucleus of the hypothalamus may play a major role in thermoregulation. 26 In a previous report,
-tetrahydrocannabinol, a CB1-receptor agonist, injected directly into the hypothalamus produced dose-dependent hypothermia. 27 Similarly, WIN55212-2, which was used as a CB1-receptor agonist in this study, induced profound hypothermia and was blocked by pretreatment with SR141716A (3 and 10 mg kg
À1
). 28 With Compound-1, it significantly antagonized CB1-agonist-induced hypothermia in mice only treated with a dose of 100 mg kg À1 (Figure 4 ).
Based on these results, it can be concluded that even though pharmacokinetic properties of Compound-1 are more favorable than those of SR141716A, its site of action can be limited to peripheral CB1 receptors especially at low doses because of its low BBB permeability. P-glycoprotein (P-gp), the predominant efflux transporter in brain, can be one of the possible reasons for low BBB permeability of Compound-1. Therefore, additional human P-gp ATPase assay was conducted to estimate whether or not P-gp is involved in the BBB penetration of Compound-1 and SR141716A. From the result obtained it was shown that both Compound-1 and SR1411716A were not P-gp substrates (data not shown). Hence, it seems that this discrepancy is not due to P-gp. Although the exact mechanism is not clear, other transporters than P-gp, brain metabolism and plasma protein binding can be possible reasons.
When the anorexic effects of these two compounds were measured in regular-diet-or HF diet-supplied mice, the potency ratios under both conditions were similar to that of the CB1-receptor binding affinity in vitro. However, HF-DIO mice showed higher susceptibility than regular-diet-fed mice for the anorexic effects of these two compounds. These differences may be due to a highly activated EC system in HF-DIO mice as compared with that in regular-diet-supplied mice. 4, 29 As Compound-1 is peripherally more selective and potent enough to discriminate the central and peripheral effects, we further examined the contribution of peripheral CB1 receptors in the antiobesity activities of CB1 antagonist using chronic animal models. In HF-DIO mice treated by 10 mg kg À1 of Compound-1, its plasma concentration was 7.6 times higher than that of 10 mg kg À1 SR141716A-treated HF-DIO mice (Table 1) . Although this pharmacokinetic property of Compound-1 can compensate for weak binding affinity to CB1 receptor as compared with that of SR141716A, it is interesting to see that it did not show any antiobesity activity at 10 mg kg À1 in the experiment using HF-DIO mice. This result indicates that the weak antiobesity effect of Compound-1 may result from the low BBB permeability of Compound-1, but not from low plasma concentration, which is supported by our prediction using the brain uptake data ( Figure 3 ). As shown in Table 1 , when administered at 10 mg kg À1 , the brain concentration of
Compound-1 was almost same as that of SR14716A when administered at 10 mg kg À1 even though the plasma concentration of Compound-1 was 7.6 times higher than that of SR141716A. On the other hand, when administered at 100 mg kg
, the brain concentration of Compound-1 was Central cannabinoid plays a major role in adiposity M-H Son et al 7.2 times higher than that of SR14716A when administered at 10 mg kg
, which corresponds to our in vitro potency ratio. Therefore, the fact that the antiobesity effect of Compound-1 at 100 mg kg À1 was comparable to that of SR141716A at 10 mg kg À1 is mainly due to lower BBB permeability with weak binding affinity to CB1 receptor in spite of higher plasma concentration. Treatment with SR141716A or Compound-1 reduced food intake, which recovered to baseline levels after day 12 (Figure 6b ). On the other hand, antiobesity effects remained unchanged throughout the experimental periods (Figure 6a) . These results coincide with previous reports that chronic treatment with CB1 antagonist caused transient reduction in food intake and a more prolonged reduction in body weight.
14 These were interpreted as the results of regulation of lipolysis and energy balance by direct inhibition of peripherally located CB1 receptors. 30, 31 However, it remains to be elucidated whether the role of central CB1 receptor is involved in energy balance or not. In order to evaluate whether Compound-1 is a peripherally acting antagonist, we tested the inhibition of hepatic SREBP1c expression. Although the lowest dose of Compound-1 completely inhibited elevated hepatic SREBP-1c expression, Compound-1 did not induce anorexia or body weight reduction ( Figure 7) . These results suggest that total inhibition of peripheral CB1 receptor may not be sufficient to have a full and complete antiobesity activity.
These results strongly suggest that (1) central CB1 receptor mediates the anorexic response of CB1-receptor antagonist and (2) peripheral modulations, including inhibition of hepatic fatty acid synthesis mediated by SREBP-1c, are not major mechanisms involved in the antiobesity effects of CB1-receptor antagonist.
